From Targets to Hits in Drug Discovery 

You could have discovered the future of drug discovery at The Inaugural Hit ID Summit! As chemical libraries and hit screening methods—including DNA-encoded libraries, high-throughput screening, fragment-based screening, and AI—continue to evolve, now is the time for medicinal chemists, computational chemists, and drug discovery leaders and innovators to unite at a dedicated forum. This unique event presented the opportunity to share innovative ideas and actionable insights that would revolutionize hit finding strategies and propel the entire drug development process forward. From delving into the latest hit-finding technologies and methodologies, bridging the gap from target identification to molecule discovery and transforming hits into promising leads.  

You could have joined us for an unmissable experience where the biggest names in pharma and biotech came together including Bristol Myers Squibb, GlaxoSmithKline, Insitro, Sanofi & more. This was your chance to stay ahead of the curve and drive innovation in your hit identification and drug discovery strategies. 

This summit was a unique opportunity to network with over 50 hit strategy specialists and drug discovery experts. With insights from industry giants like AbbVie, Novartis, Pfizer, Sanofi, and UCB, you could have gained invaluable knowledge and forged meaningful connections that would have taken your work to the next level.